About the Authors
- Patricia Nahirya-Ntege
-
Affiliation MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
- Adrian Cook
-
* E-mail: adc@ctu.mrc.ac.uk
Affiliation MRC Clinical Trials Unit, London, United Kingdom
- Tichaona Vhembo
-
Affiliation University of Zimbabwe Medical School, Harare, Zimbabwe
- Wilfred Opilo
-
Affiliation Joint Clinical Research Centre, Kampala, Uganda
- Rachel Namuddu
-
Affiliation Baylor-Uganda Paediatric Infectious Disease Clinic, Mulago Hospital, Kampala, Uganda
- Richard Katuramu
-
Affiliation MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda
- Jessica Tezikyabbiri
-
Affiliation Joint Clinical Research Centre, Kampala, Uganda
- Bethany Naidoo-James
-
Affiliation MRC Clinical Trials Unit, London, United Kingdom
- Diana Gibb
-
Affiliation MRC Clinical Trials Unit, London, United Kingdom
- on behalf of the ARROW Trial Team
Competing Interests
First–line drugs were provided by GlaxoSmithKline. No other competing interests exist. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Analyzed the data: AC. Wrote the paper: PNN AC TV RK RN WO JT BN DG.